1887
5 - The 12th international scientific conference of Al-Nahrain University
  • ISSN: 1999-7086
  • EISSN: 1999-7094

Abstract

A global health concern is methicillin-resistant (MRSA). The use of bacteriophages is one of the many novel control strategies against MRSA that are frequently sought. However, it is quite challenging to isolate enough lytic anti-MRSA phages. In order to extract, optimize, and remodel anti-MRSA phages, this study sought novel approaches.

Two ATCC MRSA strains and nine clinical MRSA isolates were used to isolate wild anti-MRSA phages from hospital settings, dirt, and sewage. The wild phages were optimized using plaque-based biokinetic techniques. Using chemicals that weakened bacterial cell walls, the resulting highly lytic and specific anti-MRSA phages were subjected to unique physicochemical phage redesign processes. This allowed the phages to enter host bacteria and acquire the specificity of the new host. Three different protocols were tested using combinations of Tween 20, lysozyme, and nisin A.

Nisin A and lysozyme protocols at different rates were found to be successful in producing newly redesigned, transiently stable, anti-MRSA phages.

Unlike self-depleting antibiotic-based applications, phage redesign is self-fortifying. In order to address the increasing number of epidemic MRSA strains, this model could prove to be a perfect platform for developing trustworthy control and treatment strategies. Additionally, it is believed to be an infinite supply of anti-MRSA lytic phages from which several permanent phage lysins can be isolated and refined.

Loading

Article metrics loading...

/content/journals/10.5339/jemtac.2024.iscncm.3
2024-11-18
2025-01-10
Loading full text...

Full text loading...

/deliver/fulltext/jemtac/2024/5/jemtac.2024.iscncm.3.html?itemId=/content/journals/10.5339/jemtac.2024.iscncm.3&mimeType=html&fmt=ahah

References

  1. Patil SS, Suresh KP, Shinduja R, Amachawadi RG, Chandrashekar S, Pradeep S, et al. Prevalence of methicillin-resistant Staphylococcus aureus in India: A systematic review and meta-analysis. Oman Med J. 2022 Jul 31;37(4):e440. doi: 10.5001/omj.2022.22.
    [Google Scholar]
  2. Preeja PP, Kumar SH, Shetty V. Prevalence and characterization of methicillin-resistant Staphylococcus aureus from community- and hospital-associated infections: A tertiary care center study Antibiotics (Basel). 2021 Feb 18;10(2):197. doi: 10.3390/antibiotics10020197.
    [Google Scholar]
  3. Ayobami O, Brinkwirth S, Eckmanns T, Markwart R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low- and lower-middle-income countries: A systematic review and meta-analysis Emerg Microbes Infect. 2022 Dec;11(1):443–51. doi: 10.1080/22221751.2022.2030196.
    [Google Scholar]
  4. Abdulamir AS. Novel methods to design wild bacteriophages into highly lytic and therapeutic bacteriophages to extensively drug-resistant Mycobacterium tuberculosis. J Fac Med Bagdad. 2016;58(3):276–82. doi: 10.32007/jfacmedbagdad.583264.
    [Google Scholar]
  5. Alaamery SK, Al-Hayanni HSA. The antibacterial and anti-biofilm effects of Sumac (Rhus coriaria L) fruit extracts against some multidrug-resistant pathogenic bacteria J Fac Med Bagdad. 2022 Oct 17;64(3):183–8. doi: 10.32007/jfacmedbagdad.6431964.
    [Google Scholar]
  6. Hussein N, Salih RS, Rasheed NA. Prevalence of methicillin-resistant Staphylococcus aureus in Hospitals and Community in Duhok, Kurdistan Region of Iraq. Int J Infect. 2019 Jul;6(2):e89636. doi: 10.5812/iji.89636.
    [Google Scholar]
  7. Hantoosh SM. Nasal carriage of vancomycin- and methicillin-resistant Staphylococcus aureus among intermediate students of urban and rural schools of Muthanna Province in Iraq. Iraqi J Pharm Sci. 2022 Jun 12;31(1):102–8. doi: 10.31351/vol31iss1pp102-108.
    [Google Scholar]
  8. Mekonnen SA, Palma Medina LM, Michalik S, Loreti MG, Gesell Salazar M, van Dijl JM, et al. Metabolic niche adaptation of community- and hospital-associated methicillin-resistant Staphylococcus aureus. J Proteomics. 2019 Feb 20;193:154–61. doi: 10.1016/j.jprot.2018.10.005.
    [Google Scholar]
  9. Burgin DJ, Liu R, Hsieh RC, Heinzinger LR, Otto M. Investigational agents for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) bacteremia: progress in clinical trials Expert Opin Investig Drugs. 2022 Mar;31(3):263–79. doi: 10.1080/13543784.2022.2040015.
    [Google Scholar]
  10. Abdulamir AS, Jassim SAA, Hafidh RR, Bakar FA. The potential of bacteriophage cocktail in eliminating methicillinresistant Staphylococcus aureus biofilms in terms of different extracellular matrices expressed by PIA, ciaA-D, and FnBPA genes. Ann Clin Microbiol Antimicrob. 2015 Nov 11;14:49. doi: 10.1186/s12941-015-0106-0.
    [Google Scholar]
  11. Li X, Chen Y, Wang S, Duan X, Zhang F, Guo A, et al. Exploring the benefits of metal ions in phage cocktail for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) infection. Infect Drug Resist. 2022 May 27;15:2689–702. doi: 10.2147/IDR.S362743.
    [Google Scholar]
  12. Moorthy GS, Greenberg RG, Hornik CD, Cassino C, Ghahramani P, Kumar KR, et al. Safety and pharmacokinetics of exebacase in an infant with disseminated Staphylococcus aureus infection. Clin Infect Dis. 2022 Aug 25;75(2):338–41. doi: 10.1093/cid/ciab1015.
    [Google Scholar]
  13. Guo Y, Song G, Sun M, Wang J, Wang Y. Prevalence and therapies of antibiotic-resistance in Staphylococcus aureus Front Cell Infect Microbiol. 2020 Mar 17;10:107. doi: 10.3389/fcimb.2020.00107.
    [Google Scholar]
  14. Wan L, Ye C, Li B, Soteyome T, Bao X, Lu Z, et al. Antimicrobial susceptibility and genetic features of a heterogeneous vancomycin intermediate-resistant Staphylococcus aureus strain. Infect Genet Evol. 2020 Nov;85:104565. doi: 10.1016/j.meegid.2020.104565.
    [Google Scholar]
  15. McGuinness WA, Malachowa N, DeLeo FR. Vancomycin resistance in Staphylococcus aureus Yale J Biol Med. 2017 Jun 23;90(2):269–81. https://pubmed.ncbi.nlm.nih.gov/28656013/.
    [Google Scholar]
  16. Ahmed SH, Hafidh RR. The isolation of specifically lytic phages along with their extracted endolysins as antibacterial agents to MDR Enterococcus faecalis Res J Pharm Technol. 2021; 14(9):4547–54. doi: 10.52711/0974-360X.2021.00791.
    [Google Scholar]
/content/journals/10.5339/jemtac.2024.iscncm.3
Loading
/content/journals/10.5339/jemtac.2024.iscncm.3
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error